Back
Monopar Therapeutics Stock Price Chart
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
53
MNPR
Monopar Therapeutics
Last Price:
$41.57
Seasonality Move:
-10.26%
7 Day Trial
ALL ACCESS PASS
$
7
-
The current trend is moderately bullish and MNPR is experiencing slight selling pressure.
Monopar Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 41.3 | Buy |
| 20-day SMA: | 36.92 | Buy |
| 50-day SMA: | 36.14 | Buy |
| 200-day SMA: | 20.45 | Buy |
| 8-day EMA: | 41.14 | Buy |
| 20-day EMA: | 38.5 | Buy |
| 50-day EMA: | 36.36 | Buy |
| 200-day EMA: | 24.53 | Buy |
Monopar Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 2 | Buy |
| Relative Strength Index (14 RSI): | 58.85 | Buy |
| Chaikin Money Flow: | -8042 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (32.95 - 41.69) | Buy |
| Bollinger Bands (100): | (25.32 - 41.8) | Buy |
Monopar Therapeutics Technical Analysis
| Apr 11 | Apr 14 | Apr 15 | Apr 16 | Apr 17 | Apr 21 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 11 | 14 | 15 | 16 | 17 | 21 | 22 | 23 | 24 | 25 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Monopar Therapeutics Stock
Is Monopar Therapeutics Stock a Buy?
-
Monopar Therapeutics share price is 42.71 while MNPR 8-day simple moving average is 41.30, which is a Buy signal.
-
The stock price of MNPR is 42.71 while Monopar Therapeutics 20-day SMA is 36.92, which makes it a Buy.
-
Monopar Therapeutics 50-day simple moving average is 36.14 while MNPR share price is 42.71, making it a Buy technically.
-
MNPR stock price is 42.71 and Monopar Therapeutics 200-day simple moving average is 20.45, creating a Buy signal.
MNPR Technical Analysis vs Fundamental Analysis
Buy
53
Monopar Therapeutics (MNPR)
is a Buy
Is Monopar Therapeutics a Buy or a Sell?
-
Monopar Therapeutics stock is rated a BuyThe current Monopar Therapeutics [MNPR] share price is $42.71. The Score for MNPR is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.
Monopar Therapeutics Stock Info
Market Cap:
261.1M
Price in USD:
42.71
Share Volume:
16.2K
Monopar Therapeutics 52-Week Range
52-Week High:
54.30
52-Week Low:
1.72
Buy
53
Monopar Therapeutics (MNPR)
is a Buy
Monopar Therapeutics Share Price Forecast
-
What is the Monopar Therapeutics stock price today?The Monopar Therapeutics stock price is 42.71 USD today.
-
Will MNPR stock go up or go down?Monopar Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Monopar Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Monopar Therapeutics is not overvalued.
Is Monopar Therapeutics Stock a Buy?
-
Monopar Therapeutics share price is 42.71 while MNPR 8-day exponential moving average is 41.14, which is a Buy signal.
-
The stock price of MNPR is 42.71 while Monopar Therapeutics 20-day EMA is 38.50, which makes it a Buy.
-
Monopar Therapeutics 50-day exponential moving average is 36.36 while MNPR share price is 42.71, making it a Buy technically.
-
MNPR stock price is 42.71 and Monopar Therapeutics 200-day simple moving average is 24.53, creating a Buy signal.
Fundamental Analysis of Monopar Therapeutics
Is Monopar Therapeutics a good investment?
-
Analysts estimate an earnings decrease this quarter of $0.46 per share, an increase next quarter of $0.13 per share, a decrease this year of $0.86 per share, and an increase next year of $0.69 per share.
Technical Analysis of Monopar Therapeutics
Should I short Monopar Therapeutics stock?
-
MNPR Moving Average Covergence Divergence (MACD) indicator is 2, suggesting Monopar Therapeutics is a Buy
-
Monopar Therapeutics Relative Strength Index (RSI) is 58.85, which suggest Monopar Therapeutics is overbought
-
The Bollinger Bands (25) for Monopar Therapeutics is (32.95 - 41.69), which suggest Monopar Therapeutics is a Buy
-
The Bollinger Bands (100) for Monopar Therapeutics is (25.32 - 41.8), which suggest Monopar Therapeutics is a Buy
* Monopar Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.